These results are consistent with PTPN2‐deficient HER‐2 CAR T cells completely eliminating HER‐2‐expressing tumours and eliciting a selective pressure so that any re‐emerging tumours downregulate HER‐2. Here, ERBB2 is linked to neoplasm.